000099333 001__ 99333
000099333 005__ 20210224140106.0
000099333 0247_ $$2doi$$a10.1016/j.jhep.2019.08.010
000099333 0248_ $$2sideral$$a122920
000099333 037__ $$aART-2019-122920
000099333 041__ $$aeng
000099333 100__ $$aVrancken, B.
000099333 245__ $$aCross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
000099333 260__ $$c2019
000099333 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099333 5203_ $$aTo the Editor:
As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID), 2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.
As the chronic nature of most HCV infections hampers reliably reconstructing contact networks from patient interviews, virus genetic data can be a valuable alternative source of information for elucidating the geographic history of virus lineages (e.g. [5], [6]). Using such data, we have recently shown that for the most prevalent subtype among PWID in Spain (40%, 7), HCV1a, infections often link to infections abroad – in recent years >50% link to Western European countries, mostly European Union (EU) member states – as opposed to other infections ...
000099333 536__ $$9info:eu-repo/grantAgreement/ES/FEDER/RD16-0025-0040$$9info:eu-repo/grantAgreement/ES/ISCIII/PI15-00713
000099333 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000099333 590__ $$a20.582$$b2019
000099333 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b2 / 88 = 0.023$$c2019$$dQ1$$eT1
000099333 592__ $$a6.817$$b2019
000099333 593__ $$aHepatology$$c2019$$dQ1
000099333 655_4 $$ainfo:eu-repo/semantics/other$$vinfo:eu-repo/semantics/acceptedVersion
000099333 700__ $$aCuypers, L.
000099333 700__ $$aPérez, A.B.
000099333 700__ $$aChueca, N.
000099333 700__ $$aAnton-Basantas, J.
000099333 700__ $$ade la Iglesia, A.
000099333 700__ $$0(orcid)0000-0001-8637-510X$$aFuentes, J.$$uUniversidad de Zaragoza
000099333 700__ $$aPineda, J.A.
000099333 700__ $$aTéllez, F.
000099333 700__ $$aBernal, E.
000099333 700__ $$aRincón, P.
000099333 700__ $$aVon Wichman, M.A.
000099333 700__ $$aFuentes, A.
000099333 700__ $$aVera, F.
000099333 700__ $$aRivero-Juárez, A.
000099333 700__ $$aJiménez, M.
000099333 700__ $$aVandamme, A.M.
000099333 700__ $$aGarcía, F.
000099333 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000099333 773__ $$g71, 6 (2019), 1270-1272$$pJ. hepatol.$$tJOURNAL OF HEPATOLOGY$$x0168-8278
000099333 8564_ $$s299770$$uhttps://zaguan.unizar.es/record/99333/files/texto_completo.pdf$$yPostprint
000099333 8564_ $$s3561396$$uhttps://zaguan.unizar.es/record/99333/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000099333 909CO $$ooai:zaguan.unizar.es:99333$$particulos$$pdriver
000099333 951__ $$a2021-02-24-12:54:45
000099333 980__ $$aARTICLE